Drug Discovery

Generative chemistry designs novel molecular structures optimized for target binding, selectivity, and drug-like properties. Protein structure prediction (AlphaFold) enables structure-based drug design for previously undruggable targets. Phenotypic screening combined with AI identifies compounds that affect disease-relevant cellular behaviors. Multi-parameter optimization balances efficacy, toxicity, and manufacturability simultaneously.

AI identifies novel drug targets from multi-omic disease data. Generative models design molecules with desired binding properties. Predictive toxicology flags safety concerns before synthesis. Clinical trial design optimization improves probability of success. Drug repurposing identifies new uses for existing approved drugs.

AI-powered drug discovery is one of the highest-value applications of AI in healthcare, with the potential to reduce the $2.6 billion average cost and 10-15 year timeline of bringing new drugs to market. With 6 funders. Companies like Recursion, Insilico Medicine, and Isomorphic Labs are leading the category.